Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine.
- Author:
Eunyoung LEE
1
;
June Young CHUN
;
Kyoung Ho SONG
;
Pyoeng Gyun CHOE
;
Ji Hwan BANG
;
Eu Suk KIM
;
Hong Bin KIM
;
Sang Won PARK
;
Nam Joong KIM
;
Wan Beom PARK
;
Myoung don OH
Author Information
- Publication Type:Original Article
- Keywords: Zoster vaccine; Herpes zoster; Immunogenicity; Enzyme-linked immunosorbent assay; Enzyme-linked immunospot assay
- MeSH: Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Glycoproteins; Herpes Zoster Vaccine*; Herpes Zoster*; Herpesvirus 3, Human; Immunoglobulin G; Observational Study; Prospective Studies*; T-Lymphocytes; Vaccination*
- From:Infection and Chemotherapy 2018;50(4):311-318
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Zoster vaccination is recommended for people with a history of herpes zoster (HZ), but the most effective timing of vaccine administration after zoster illness is unresolved. This prospective observational study compared the immunogenicity and safety of administering HZ vaccine at 6-12 months and 1-5 years after zoster illness. MATERIALS AND METHODS: Blood samples were collected before the administration of live zoster vaccine and 6 weeks after vaccination. Varicella-zoster virus (VZV) IgG concentrations and T-cell responses were assessed by glycoprotein enzyme-linked immunosorbent assay and interferon-γ enzyme-linked immunospot assay (ELISPOT), respectively. RESULTS: The baseline geometric mean value (GMV) of VZV IgG was higher in the 6-12 months group than in the 1-5 years group (245.5 IU/mL vs. 125.9 IU/mL; P = 0.021). However, the GMV increased significantly in both groups (P = 0.002 in the 6-12 months group; P <0.001 in the 1-5 years group). The results of the ELISPOT assay were not significant for differences of the GMV between baseline and 6-week post-vaccination groups, while the GMV increased significantly in both groups (P = 0.001 in the 6-12 months group; P <0.001 in the 1-5 years group). CONCLUSION: The immunogenicity of zoster vaccine may be similar whether administered 6-12 months, or >1 year after zoster illness. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02704572
